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The Legal Aspects of Chemical
Restraint Use in Nursing Homes
Chemical restraint,the excessive control of behavior by the use of medication, is just one of the many risks faced
by the residents of nursing homes. This
article explores the definition of chemical restraint,its adverse effect, relevant
federal and state laws and regulation,
customary industry practice, and practice tips for correcting discovered

abuse.
By Julie A. Braun and
Lawrence A. Frolik
Julie A. Braun, J.D., L.L.M. is a Chicago-based health
law attorney and writer. She is Co-Chair Elect of the
American Bar Association Torts and Insurance Practice
Section Medicine and Law Committee and former Vice
Chair of its Seniors' Law Committee. She teaches,
writes, and lectures nationally on health law subjects.
Lawrence A. Frolik is a Professor of Law at the
University of Pittsburgh School of Law. He is the coauthor (with M. Brown) of Advising the Elderly or
Disabled Client (2d ed., Warren Gorham & Lamont),
Residence Options for the Older or Disabled Client
(Warren Gorham & Lamont), and Aging and the Law:
An InterdisciplinaryReader (Temple University Press).

he 1.6 million people who live in the
nation's nursing homes are a highly vulnerable population. Among the risks
faced by nursing home residents are
excessive behavior control and restraint
by the use of medication, commonly referred to as
chemical restraint. "[M]edication, when used judiciously, can be a valuable adjunct in maximizing
function and maintaining well-being in elderly
nursing home residents. When used inappropriately, [it] can be an instrument of harm, abuse, negligence and malpractice."' Of course, drugs are used
for a variety of purposes and may have a positive
value as part of a well-planned therapeutic strategy.
For example, absent treatment, severe depression
can lead to suicide or indirect life-threatening
behavior such as a failure to eat. Too often, however, drugs are used without adequate monitoring
for harmful side effects, or even worse, are used to
restrain rather than help the resident. Moreover,
many, if not most, residents take multiple drugs, a
practice known as polypharmacy. 2 How many is
too many? While no precise guidelines exist, it is
known that as the number of prescription drugs
increases, the likelihood of drug interactions, toxicity, and side effects increases exponentially for the
older adult.' Five drugs or more in a treatment regimen arouses concern; ten or more sharply increases the likelihood that the resident will experience
deleterious side effects. 4
What Are Chemical Restraints?
Chemical restraints include "any drug that is used
for discipline or convenience and not required to
treat medical symptoms."' Interestingly, this definition no longer singles out psychopharmacological
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drugs.6 Removing the term psychopharmacological
from the standard acknowledges that a wide range
of drugs may be used as chemical restraints.
Discipline means "any action taken by the facility
for the purpose of punishing or penalizing residents." 7 Convenience involves actions taken by the
facility to reduce its burdens rather than to promote the best interest of the resident
Older nursing home residents who suffer from
mental disability are often prescribed psychotropic
medications. Commonly prescribed psychotropic9
medications appear in Table 1 0 This list is not
exhaustive; new drugs continue to be developed
and employed.

Adverse Effects of Chemical Restraint
When used properly, psychotropic drugs can be an
important treatment therapy. Unfortunately, such
drugs can also be used to control or chemically
restrain residents who would otherwise pose
behavioral problems. A growing awareness of the
risk of chemical restraint has led to an examination
and reevaluation of drug use in long-term care

facilities. (Even drugs prescribed for medically
sound reasons may have harmful side effects particularly when they interact and when used with
over-the-counter drugs.)
Aging affects how the body handles a drug (that
is, movement into, around, and out of the body) as
well as the specific action of the drug itself on the
older person's body. A review of nineteen clinical
studies concluded that a substantial number of
nursing home residents who were taking psychotropic drugs on a regular, long-term basis suffered harmful side effects." A 1997 report released
by the Office of Inspector General Department of
Health and Human Services arrived at a similar
conclusion.' 2 Numerous drugs and drug combinations place persons over the age of sixty-five at
13
greater risk of adverse drug outcomes.
Not surprisingly, overuse of drugs erodes the
resident's autonomy. Overdrugged residents may
not speak or think clearly and exhibit less interest
in self-care. Other consequences of over-reliance on
drugs or the resort to chemical restraint include the
risks presented in Table 2."

Table 1. Psychotropic Medications (generic name followed by brand name in parentheses)
Antidepressant Medications
Imipramine (Tofranil)
Desipramine (Norpramin)
Doxepin (Adapin, Sinequan)
Nortriptyline (Aventyl, Pamelor)
Fluoxetine (Prozac)
Sertraline (Zoloft)
Trazodone (Desyrel)
Antipsychotic Medications
Haloperidol (Haldol)
Thioridazine (Mellaril)
Thiothixene (Navane)
Chlorpromazine (Thorazine)
Risperidone (Risperdal)
Olanzapine (Zyprexa)
Mood Stabilizers
Lithium carbonate (several brands)
Valproic acid (Depakene)
*

Anxiolytic Medications
(counteract or diminish anxiety)*
Oxazepam (Serax)
Alprazolam (Xanax)
Diazepam (Valium)
Lorazepam (Ativan)
Diphenhydramine (Benadryl)
Hydroxyzine (Atarax, Vistaril)
Buspirone (BuSpar)
Sedative-Hypnotic Medications**
(sleep inducers)
Flurazepam (Dalmane)
Temazepam (Restoril)
Lorazepam (Ativan)
Oxazepam (Serax)
Diphenhydramine (Benadryl)
Hydroxyzine (Atarax, Vistaril)
Chloral hydrate (several brands)

TABER'S CYCLOPEDIC MEDICAL DICTIONARY, 129 (17th ed. 1993) (defining anxiolytic).
* Id. at 944, 1773 (defining hypnotics and sedative, respectively).
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Table 2. Consequences of Chemical Restraint
* Agitation
* Gait disturbance
* Memory impairment
* Sedation
* Withdrawal

e Functional decline
9 Increased fall risk
o Movement disorders
* Orthostatic/Postural
hypotension

Increased Fall Risk
"An increase in body sway or unsteadiness has
been demonstrated shortly after the administration
of psychotropic medications" in the older adult.'5
Any drug that interferes with the resident's postural control, cerebral perfusion, or cognitive function
may potentially influence a resident's gait and balance and induce a fall. 6 Injuries suffered as a result
17
of the fall may lead to further decline.
Orthostatic/PosturalHypotensionm
Medications with anticholinergic" properties (for
example, tricyclic antidepressant drug therapy) may
cause a drop in blood pressure when the patient
attempts to stand. This may result in dizziness,
fainting, falls, and even heart attack or stroke.2"
Sedation
Older residents are more vulnerable to the common
side effects of psychotropic medication, such as
sedation, and may experience drowsiness or
decreased consciousness. Families who find a relative unresponsive or difficult to wake should investigate whether staff members are using drugs merely to make the resident more quiescent and easier
to care for. If so, there may be grounds for a successful lawsuit.
Movement Disorders
Some psychotropic drugs cause a complete or partial loss of muscle movement that markedly
decreases body activity (akinesia);2 1 motor restlessness-an inability to sit still (akathisia);22 muscle
spasms of the eye, neck, and back (dystonias);23
stiffness, rigidity, tremor, and drooling (symptoms
resembling Parkinson's disease);2 4 and slow, rhythmical, involuntary, repetitive, purposeless movements involving the eyes, face, mouth, tongue,
trunk, and limbs (tardive dyskinesia).25

23

Memory Impairment
Psychotropic medications may cause the patient to
become confused, disoriented, or suffer amnesia.
Functional Decline
Many residents who receive psychotropic drugs
suffer functional decline in activities of daily living
such as eating, walking, dressing, using a wheelchair, or using the restroom. If the decline is not
reversed, the resident is at risk of malnutrition,
contractures, aspiration pneumonia, and pressure
26
sores.

Agitation
Sedative or hypnotic drugs may cause some
patients to become agitated, experience insomnia,
hallucinations, nightmares, and become hostile or
even violent.
Withdrawal
Even taking the resident off the drugs can be problematic. Many residents suffer severe physical or
psychological withdrawal symptoms. To avoid
these and other harmful effects, drugs must be carefully prescribed and monitored. Any side effects
must be documented, and the resident's behavior
monitored.
Federal Law and Regulation
For years nursing homes felt free to use drugs as a
form of chemical restraint.27 This pattern of practice changed dramatically with the passage of the
landmark nursing home reforms contained within
the Omnibus Budget Reconciliation Act of 1987
(OBRA '87).28 The OBRA '87 contains the Nursing
Home Bill of Rights2 9 that applies to residents of
facilities certified for participation in the Medicare
and Medicaid programs, the primary funders of
long-term care.3" (Implementing regulations appear
in Title 42 of the Code of Federal Regulations.3 1 )
The Health Care Financing Administration
(HCFA), within the Department of Health and
Human Services is responsible for ensuring the
quality of nursing homes as part of its oversight of
the
Medicare
and
Medicaid
programs.
Government surveyors rely on HCFA guidelines,
which are periodically updated, when they evaluate
compliance with, among other things, the appropriateness of chemical restraint.

Elder's Advisor

Freedom from Chemical Restraint
The Nursing Home Bill of Rights specifically states
that nursing home residents have "the right to be
free from physical or mental abuse, corporal punishment, involuntary seclusion, and any physical or
chemical restraints imposed for purposes of discipline or convenience, and not required to treat the
resident's medical symptoms."3 2 The statute further
states that "physical or chemical restraints may
only be imposed.. .to ensure the33physical safety of
the resident or other residents."
InterdisciplinaryApproach to Resident Care
Under federal law each resident must receive the
care needed to "attain or maintain the highest practicable physical, mental, and psychosocial wellbeing." 34 A nursing home is required to create a
comprehensive interdisciplinary clinical evaluation
and care plan that demonstrates how it expects to
assist the resident in reaching his or her highest
level of well-being.3" An interdisciplinary geriatric
team may consist of a physician, nurse, pharmacist,
activities therapist, occupational and physical therapists, speech and language pathologist, or a social
worker.36 The team creates a care plan, which might
include the use of drugs. If, however, the plan does
not, any use of drugs represents an unacceptable
and illegal form of control or restraint.
The Need for Informed Consent
Even if the care plan recommends the use of drugs,
the resident must consent to such use. Residents, or
their legal health care decision-makers, must give
informed consent before they are given drugs for
any purpose, including as a device to control
behavior.37 The risks, benefits, and alternatives to
restraint must be explained in the context of the
resident's condition, circumstances, and environment. The resident has the right to refuse or accept
chemical restraint38 even if the resident's physician
recommends the medication, or the facility claims
that without it the resident is too difficult to manage.39 Significantly, a resident's refusal does not
absolve the facility from providing care that allows
the resident to attain or maintain the highest practicable physical, mental, or psychosocial wellbeing.
When a resident is incapable of making an
informed decision, the resident's legal surrogate or
representative may exercise the right based on the
same information that would have been provided

to the resident. ° However, the legal surrogate or
representative cannot give permission to use chemical restraints for discipline or staff convenience or
when the restraint is not necessary to treat the resident's medical symptoms." Residents can state in
their advance health care directives their preferences concerning chemical restraint use.42
Physician Order Required
Assuming that proper informed consent to the use
of a drug has been obtained, it can be used "only
upon the written order of a physician that specifies
the duration and circumstances under which the
restraints are to be used."43 The physician's order
will appear directly in the nursing home resident's
record or as a telephone order later signed by the
physician. In an emergency, however, chemical
restraints may be used without a physician's order
unless the nursing home has been previously notified that such treatment is not acceptable.44
Federal Law Prohibits Unnecessary Drugs
Federal law requires that "[e]ach resident's drug
regimen must be free from unnecessary drugs. " "
According to federal regulations, an unnecessary
drug is any drug used:46
" in excessive dosage, including duplicate drug
therapy;
" for excessive duration;
" without adequate monitoring;
" without adequate indications for its use;
" in the presence of adverse consequences which
indicate that use of the drug should be
reduced or discontinued; or
" any combination of the reasons above.4
Check the surveyor's guidelines interpreting the
federal regulations for acceptable dosages for specific medications. For example, daily use is equal to
or less than 7.5 mg by mouth for temazepam
(Restoril), a drug for sleep induction, unless higher
doses (as evidenced by the resident's response
and/or clinical record) are necessary for maintenance or improvement in the resident's functional
status.48
Although the federal guidelines do not create a
private right of action, there have been successful
civil suits for damages caused by excessive drug
use. For example, a $908,800 settlement was
reached in a case involving a sixty-one-year-old
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nursing home resident who was given too much
Lithium, a drug with a narrow safety margin. 9 The
plaintiff claimed that excessive doses of Lithium
were given over a three-week period, resulting in
acute Lithium toxicity and cognitive brain dam50
age.
Gradual Dose Reduction
If the resident is a victim of chemical restraint, the
reduction of drug dosages must be carefully monitored. There should be a systematic and gradual
process of reducing or discontinuing the drugs that
follow a physician-approved care plan.' "Gradual
dosage reductions consist of tapering the resident's
daily dosage to determine whether the resident's
symptoms can be controlled by a lower dose or if
the drug can be eliminated altogether." 2 Federal
regulatory guidelines identify time periods within
which gradual dose reduction should be attempted.
For example, a gradual dose reduction should be
attempted at least twice within one year for benzodiazepines.53 For drugs in the sedative-hypnotic
class, a gradual dose reduction is recommended at
least three times within six months before concluding that a gradual dose reduction is clinically contraindicated s4 Antipsychotic and antidepressant
dose reduction, but no
medications require gradual
5
time period is suggested.
Response to Federal Law and Regulation
Thanks to federal and state regulations, there
appears to be a reduction in the use of chemical
restraints in nursing homes.5 6 Clinicians report
that OBRA '87 mandates regarding drug usage
have increased awareness of chemical restraint 7
and have significantly reduced the excessive use of
drugs in nursing homes.5 s Still, resident advocacy
groups, such as the National Citizens' Coalition
for Nursing Home Reform, claim that the use of
psychotropic medication remains unnecessarily
59
high.
State Law and Regulation
Virtually every state regulates restraint use in nursing homes. For example, Arkansas law prohibits
chemical restraint unless authorized by a physician
for a specified time period or needed for an emergency.6 Residents injured by a facility's violation of
this law may sue to recover actual and punitive
damages, but the court cannot award attorneys'
fees. 6 1 Colorado law limits chemical restraint to

instances when there is an emergency and no less
restrictive alternatives are available or appropriate.62 New York law requires the following controls:
" psychotropic drugs must not be used for discipline or convenience;
" psychotropic drugs must be ordered only by a
physician who specifies the problem for which
the drug is prescribed;
" psychotropic drugs may be used only as an
integral part of the resident's comprehensive
care plan and only after alternative methods
of treating the resident's condition or symptoms have been tried and have failed;
" efforts must be made to discontinue psychotropic drug use through gradual dose
reductions and behavioral interventions; and
" psychotropic drug use must be discontinued if
the harmful effects outweigh the benefits of
the drug.63
Customary Industry Practice
Nursing home risk managers and attorneys handling or defending chemical restraint cases may
find it useful to compare the frequency of chemical
restraint use in the facility in question with that of
other nursing homes. The customary industry practice, in part, establishes the legal standard of care.
Major Organizational Positions on Chemical
Restraints
When determining what constitutes unnecessary
use of drugs, courts naturally rely on relevant government statutes and regulations as well as customary industry practice. They also look to major
organizational policy statements regarding chemical restraint use as evidence of what is the appropriate standard of care. The American Association
for Geriatric Psychiatry and the American
Geriatrics Society have issued statements on the use
of psychotherapeutic medications in nursing
homes.' Both organizations "emphasize the importance of distinguishing between the appropriate use
of psychoactive medications and their misuse."65 In
addition, the American Health Care Association,
representing more than 10,500 nursing homes, has
adopted a set of practice guidelines to reduce
antipsychotic medication use in long-term care
facilities." 6
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Voluntary Accreditation Standards
The accreditation process also plays an important
role in determining industry standards. The Joint
Commission on Accreditation of Healthcare
Organizations (JCAHO) 1998-1999 Comprehensive Accreditation Manual for Long-Term Care
includes standards for chemical restraint use. 7 The
standards focus on individual resident needs and
individualized assessment. 68 The legal significance
of JCAHO standards lies in their admissibility as
evidence of the acceptable tort standard of care.69

Hypothetical Chemical Restraint Case
The difference between drug use as a form of chemical restraint versus appropriate therapy is demonstrated in the following hypothetical. °

Facts
Ann Jones, an eighty-five-year-old female with
dementia, is confined to a wheelchair because of
severe arthritis and the amputation of her right foot
from complications of diabetes. In the last few
weeks she has begun to scream, curse, and grab at
staff and visitors. During mealtimes she takes other
residents' food and casts her own food off the
table. All agree that Ann's behavior is unacceptable
and requires the use of a behavior-altering drug.

Solution A
Ann's new care plan includes pain management
and dietary assessment for food preferences and
adequacy of portions. Different behavioral strategies are initiated, including increased socialization.
Alternate feeding strategies were tried for Ann,
including a change in her feeding environment and
the type of food offered. After these behavior and
feeding strategies proved ineffective, her physician
prescribed low doses of Haldol (0.5 milligrams
every eight hours). The result was decreased agitation, more cooperation about eating, and less disruption at meals.

Solution B
The facility isolated Ann in her room where she
continued to scream loudly. She ate alone and
threw her food on the floor. The staff complained
to her physician, describing Ann as an uncooperative nuisance in need of calming down. The physician responded by ordering Haldol (1.0 milligrams
every six hours) plus Ativan (2 milligrams every six

hours) as needed. The result was that Ann became
a quiet, sleeping, drooling resident in a wheelchair.

Analysis
In Solution A, the prescribed medication was not
used as a chemical restraint because it was appropriately integrated with behavioral and feeding
strategies. Most importantly, the dosage of the
medication was not excessive. Only enough was
prescribed to calm Ann, but not enough to sedate
her.
In sharp contrast, Solution B demonstrates
inappropriate chemical restraint use (in violation of
42 C.ER. S 483.13(a)). The medication regimen
constituted unnecessary drug therapy (in violation
of 42 C.ER. S 483.25(l)(1)). No behavioral interventions were attempted (in violation of 42 C.ER.
483.25(1)(2)(ii)). In addition, multiple medications were inappropriately administered in excessive dosages without monitoring for side effects (in
violation of 42 C.ER. S 483.25(1)). The medication
was administered for staff convenience (in violation of 42 C.ER. S 483.13(a)). Moreover, Ann was
not treated with dignity (in violation of 42 C.ER.
S 483.15(a)) and was a victim of involuntary seclusion (in violation of 42 C.ER. S 483.15(a)). The
physician did not appropriately monitor changes in
the resident's medical status (in violation of 42
C.F.R. S 483.40).

Practice Tips
Understanding Medical Terminology
Attorneys who represent nursing home residents
must understand medical terminology and know
how to read the nursing home record. Unless an
attorney possesses a formal education in medicine
or nursing, the terminology found in a nursing
home record can be perplexing. A medical dictionary such as Taber's Cyclopedic Medical
Dictionary,Mosby's Drug Guide for Nurses, or the
Physician's Desk Reference7' can be helpful in
understanding the nursing home record, which
may differ materially in content and organization
from hospital or other medical facility records with
which the attorney may be familiar.

Examining the Nursing Home Record
Nursing home residents' medical charts vary in
length and complexity, depending upon the resi-
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dent's physical and mental health, the number of
persons involved in the resident's care and, to a certain extent, the sophistication of the facility. For
example, the level of documentation in a small,
rural nursing home may be quite different from the
documentation practices of a private, profit-making facility owned by a national chain.
The facility is required to maintain an individual medication record for each resident.7 2
Medication refers to all prescription and over-thecounter medications taken by the resident, including dosage, frequency of administration, and
recognition of side effects likely to occur in the resident. Though this information need not appear in
the resident's assessment, it must be included in the
resident's clinical record and care plan. Table 3
reflects some of the terminology typically encountered in a resident's medication record.
Whenever excessive or inappropriate drug use is
suspected, the attorney needs to inquire about what
drugs, in what strength and what dosage forms, are
being administered to the resident. The attorney
should also inquire when (such as daily or after
meals) and how (by mouth or intramuscular injection, for example) the drugs are administered. Each
facility will have a policy relative to dosing schedules. Usually there is an early and late medication
pass during an eight-hour shift. The morning is
when most doses are administered in long-term
care facilities. In practice, one nurse may administer medication for 30 or more residents in what is
referred to as the drug administration pass.
Even a careful examination of the resident's file
may not reveal chemical restraint. Often facility
practices may not be reflected in the resident's
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chart, or the staff may correct the paper entry
rather than the practice. Compare family and resident observations with current signed orders for
drug use. There may be fraudulent entries and
incomplete charting. Some questions to consider
include the following:
" Did a valid order for the administered drug(s)
exist?
" Was each drug administered according to the
physician's order?
" Was each drug given in the correct strength
and by the correct method?
" Was the drug used appropriate for the resident?
" Were any blank spaces detected on the medication administration record (MAR) which is
commonly kept in a notebook with the medication cart for convenience in distributing
medications to the residents?
Reviewing the Nursing Home Survey
HCFA contracts with state agencies to survey nursing homes to ensure that they meet Medicare and
Medicaid participation requirements. As part of
this oversight, state agencies are required to record
any deficiencies that exist in the homes they survey.
When inspectors cite a facility for violating a specific regulation (known as an F Tag), they also rate
the scope and severity of the violation. Inspection
reports often are difficult to read and may be quite
lengthy (over 100 pages). They usually contain professional jargon, medical terminology, and references to nursing home standards. Yet it is important to examine these inspection reports to deter-

Table 3. Principal Charting Terminology (medical abbreviation followed by definition)
qh
qd
qm
bid
bin
tid
tin
qid
qin

every hour
once a day
every morning
twice a day
twice a night
3 times a day
3 times a night
4 times a day
4 times a night

qod
qon
prn
hs
po
NPO
ac
pc
subcu

every other day
every other night
as needed
at bedtime
by mouth
nothing by mouth
before meals
after meals
subcutaneous

subq
INJ
IM
C/O
OTC
Rx
TO

subcutaneous
injection
intramuscular
complains of
over the counter
prescription treatment
telephone order
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mine whether the facility has been cited for any
deficiencies or other violations that may relate to
suspected chemical restraints.

Facility Policy and Procedure
Evidence that written institutional policies and procedures have not been enforced is often the basis
for establishing that the standard of care has not
been met. Even if the staff follows the facility procedures, however, it is possible that the nursing
home policies and procedures are not in compliance with federal and state regulations. The failure
to abide by federal or state laws may not create a
private right of action, but facility publications distributed to prospective residents or their families
may create contractual obligations that may give
rise to a cause of action based on breach of contract. Examine the admissions contract to see if it
contains language about the quality of care that
may support a claim for damages. Even medical
staff bylaw provisions and facility contracts with
physicians may contain clauses that address the use
of chemical restraint.

Constructingthe Event Chronology
When representing an injured or deceased nursing
home resident, it is important to appreciate the
timeline of events that precipitated the injury or
death. Cases involving chemical restraint often
unfold over weeks, months, or years, and may
involve complex events. These events may include
behavioral changes, institutional transfers, assessments and reassessments, multiple injuries, and
hospitalizations. A properly constructed chronology navigates the attorney through the discovery
process, including the formulation of deposition
questions. In addition, the medical chronology
assists throughout settlement negotiation and during trial. A good chronology provides more than a
summary of medical care. If the case goes to trial,
a detailed chronology will introduce the jury to the
events that led to the injuries and their sequelae.

AssessingStaff Attitude, Knowledge, and
Training
Any attempt at prophylactic actions to reduce or
forestall chemical restraint must begin with staff
attitudes. The staff must be knowledgeable about
the dangers of excessive drug use. They must be
aware of when and how to administer medication
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and the importance of monitoring for side effects.
Training is essential to minimizing use of chemical
restraint. The staff, from the governing board to
the nurses and nurses' aides, must receive comprehensive, up-to-date training regarding chemical
restraints and their alternatives. The subject should
be introduced during a new employee's orientation,
and thereafter the facility should conduct regular
staff training programs.
The American Society of Consultant Pharmacists, a national professional association representing more than 6,300 pharmacists who provide medication distribution and consultant services to manage and improve drug therapy outcomes of individuals residing in long-term care environments, recommends that nurses' aides receive four hours of inservice training per year relating to medication side
effects. 3 The American Association of Homes and
Services for the Aging agrees with the need for more
education and training for all involved parties.74 The
American Medical Directors Association (AMDA),
a major association representing physicians committed to the care of nursing facility residents, provides instruction on appropriate drug use in their
program to certify long-term care medical directors. 5 The AMDA suggests that at the facility level,
surveyors, consultant pharmacists, and physicians
should be reminded of the dangers associated with
some drugs and be directed to pursue a reduction in
their use.76

Conclusion
Attorneys who represent residents of nursing
homes or the families of such residents must be
alert for drug misuse and overuse. Any suspicion of
the use of chemical restraints should be aggressively investigated, protested, and, if necessary, prosecuted by civil suit.
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